Designer antiandrogens join the race against drug resistance.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 23580166.
- Also identified by DOI 10.7554/eLife.00692 and PMC identifier 3622176.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
By using in silico models of the complexes formed by analogues of a cancer drug and its receptor, it may be possible to strategically redesign existing drugs and win the race against mutations that lead to drug resistance in prostate cancer.
Medical subject headings
- Androgen Antagonists
- Drug Design
- Mutation